Glaukos (NYSE:GKOS) CFO Alex Thurman Sells 10,000 Shares of Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 16th. The shares were sold at an average price of $160.00, for a total value of $1,600,000.00. Following the completion of the sale, the chief financial officer owned 43,906 shares in the company, valued at $7,024,960. The trade was a 18.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Glaukos Price Performance

NYSE GKOS opened at $151.66 on Wednesday. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $161.53. The company has a market capitalization of $8.91 billion, a PE ratio of -46.24 and a beta of 0.75. The firm’s 50 day moving average is $136.27 and its 200-day moving average is $124.07.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The business had revenue of $150.57 million for the quarter, compared to analyst estimates of $137.00 million. During the same quarter in the prior year, the company posted ($0.22) earnings per share. Glaukos’s revenue was up 41.2% on a year-over-year basis. Equities research analysts anticipate that Glaukos Corporation will post -0.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC grew its holdings in shares of Glaukos by 77.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock valued at $575,844,000 after purchasing an additional 2,329,608 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Glaukos by 10.4% during the third quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock worth $292,004,000 after buying an additional 336,266 shares during the last quarter. Primecap Management Co. CA grew its stake in shares of Glaukos by 49.8% during the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after buying an additional 1,123,140 shares during the last quarter. State Street Corp grew its stake in shares of Glaukos by 0.9% during the fourth quarter. State Street Corp now owns 2,122,402 shares of the medical instruments supplier’s stock worth $239,640,000 after buying an additional 18,040 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Glaukos by 3.5% during the second quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock worth $206,503,000 after buying an additional 68,497 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on GKOS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research report on Friday, July 17th. Citigroup increased their price target on Glaukos from $162.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Wells Fargo & Company raised their price target on Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Piper Sandler reaffirmed an “overweight” rating and set a $165.00 price objective on shares of Glaukos in a research report on Wednesday, July 1st. Finally, UBS Group began coverage on shares of Glaukos in a research report on Tuesday. They set a “neutral” rating and a $150.00 price objective for the company. Twelve analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $155.23.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.